Guardant Health is an American biotechnology company co-founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The company specializes in precision oncology, developing advanced blood-based tests to detect and monitor cancer through non-invasive liquid biopsies rather than traditional tissue biopsies. Their mission is deeply personal and driven by firsthand experiences with cancer, aiming to empower patients and healthcare providers to make informed treatment decisions that improve cancer outcomes.

The company’s portfolio includes developing a blood test for early cancer screening, starting with colorectal cancer, which enables detection from a routine blood draw. Guardant Health focuses on assisting doctors in managing patients across all cancer stages—from identifying recurrence risk after surgery in early-stage cancer to selecting and monitoring treatments for advanced cancer. They are also dedicated to accelerating drug development for the biopharmaceutical industry by providing valuable genomic insights through their testing technologies.

Guardant Health holds numerous patents, including key ones acquired from Swiss biochemist Maurice Stroun, which support their innovative liquid biopsy platform. Their tests have demonstrated high accuracy in detecting genetic mutations associated with tumors, offering a comprehensive, biopsy-free cancer diagnostic option. The company went public in 2018, raising significant capital to expand their impact in precision oncology.

With a commitment to preserving the promise of every human life affected by cancer, Guardant Health continuously develops new products—having launched around 15 innovative solutions to improve cancer care. Their work not only aids in patient treatment but also enhances clinical trials and drug development processes, contributing to the next generation of precision medicines.

Headquartered in Redwood City, California, Guardant Health operates at the intersection of biotechnology and oncology, striving to transform cancer care globally through cutting-edge liquid biopsy technology and a patient-first approach.